Amarin Corp PLC (AMRN) stock
AMRNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 28, 2026Score 10/3061% above fair value
$11.27−0.04 (-0.35%)
Close on Nov 17, 2026Market cap $249.12MP/E –Yield –
Amarin total debt
Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.
Amarin's total debt was $0 at Dec 31, 2021. For fiscal 2021 it was $0. The highest annual figure on record is $105.01M in fiscal 2014.
Annual total debt
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2021 | Dec 31, 2021 | $0 | – |
| FY2020 | Dec 31, 2020 | $0 | -100.0% |
| FY2019 | Dec 31, 2019 | $50.13M | -37.6% |
| FY2018 | Dec 31, 2018 | $80.35M | -13.8% |
| FY2017 | Dec 31, 2017 | $93.18M | -7.8% |
| FY2016 | Dec 31, 2016 | $101.10M | -2.8% |
| FY2015 | Dec 31, 2015 | $103.99M | -1.0% |
| FY2014 | Dec 31, 2014 | $105.01M | +4.3% |
| FY2013 | Dec 31, 2013 | $100.69M | +18.2% |
| FY2012 | Dec 31, 2012 | $85.15M | +11045.7% |
| FY2011 | Dec 31, 2011 | $764.00K | +768.2% |
| FY2010 | Dec 31, 2010 | $88.00K | – |
Quarterly total debt
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2021 | Dec 31, 2021 | $0 | -100.0% |
| Q4 FY2020 | Dec 31, 2020 | $0 | -100.0% |
| Q3 FY2020 | Sep 30, 2020 | $9.47M | -84.2% |
| Q2 FY2020 | Jun 30, 2020 | $22.46M | -67.3% |
| Q1 FY2020 | Mar 31, 2020 | $36.98M | -50.2% |
| Q4 FY2019 | Dec 31, 2019 | $50.13M | -37.6% |
| Q3 FY2019 | Sep 30, 2019 | $60.04M | -28.6% |
| Q2 FY2019 | Jun 30, 2019 | $68.61M | -21.5% |
| Q1 FY2019 | Mar 31, 2019 | $74.30M | -17.3% |
| Q4 FY2018 | Dec 31, 2018 | $80.35M | -13.8% |
| Q3 FY2018 | Sep 30, 2018 | $84.05M | -12.2% |
| Q2 FY2018 | Jun 30, 2018 | $87.44M | -10.9% |
| Q1 FY2018 | Mar 31, 2018 | $89.85M | -9.6% |
| Q4 FY2017 | Dec 31, 2017 | $93.18M | -7.8% |
| Q3 FY2017 | Sep 30, 2017 | $95.76M | – |
| Q2 FY2017 | Jun 30, 2017 | $98.12M | – |
| Q1 FY2017 | Mar 31, 2017 | $99.41M | – |
| Q4 FY2016 | Dec 31, 2016 | $101.10M | – |
See a number that looks wrong?